A Placebo-Controlled Evaluation of the Effects of Buspirone on Smoking Cessation: Differences Between High- and Low-Anxiety Smokers
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
One hundred one smokers were divided into high and low trait anxiety groups on the basis of a normalized score on the Profile of Mood States Anxiety/Tension Scale and were randomly assigned to receive buspirone or placebo in a double-blind fashion. After a 1-week baseline, smokers were exposed to an 8-week drug and behavioral intervention involving buspirone or placebo (up to 60 mg/day) with concurrent group cognitive behavioral intervention. All smokers were to quit smoking on the target date, set at 4 weeks after the program began. Medication was provided for an additional 4 weeks after group treatment ended. The results showed that buspirone had a beneficial effect on smoking abstinence but only among smokers who were already relatively high in anxiety and only for as long as the drug was available. Moreover, when provided to smokers who were relatively low in anxiety, the drug appeared to interfere with abstinence, although these effects also reversed when the drug was withdrawn. These effects were associated with an attenuation of the expected rise in anxiety before the quit date and its actual reversal thereafter, but only in the buspirone high-anxiety group. One-month abstinence averaged 88, 61, 60, and 89% for the buspirone high-anxiety, placebo high-anxiety, buspirone low-anxiety, and placebo low-anxiety groups, respectively. By 12 months, abstinence for the buspirone and placebo high- and low-anxiety groups fell to 12, 23, 41, and 36%, respectively. No differences were observed for measures of self-efficacy, symptoms of withdrawal, medication side effects, or compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
Pomerlau (1984) · doi:10.1016/0149-7634(84)90007-1 · Cited by 378
Cited by
Smoking Cessation in Women: Special Considerations
Perkins, K. A. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00005 · Cited by 407
Us Public Health Service Clinical Practice Guideline: Treating Tobacco Use and Dependence
Fiore, M. C., & Staff, G. P. A. (2000) · Respiratory Care · doi:10.1177/002013240004501007 · Cited by 346
Neural substrates of abstinence-induced cigarette cravings in chronic smokers
Wang, Z., Faith, M., Patterson, F., Tang, K., Kerrin, K., Wileyto, E. P., Detre, J. A., & Lerman, C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2966-07.2007 · Cited by 256
Long-term outcomes of a cell phone–delivered intervention for smokers living with HIV/AIDS
Gritz, E. R., Danysh, H. E., Fletcher, F. E., Tami-Maury, I., Fingeret, M. C., King, R. M., Arduino, R. C., & Vidrine, D. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit349 · Cited by 89
Effect of Nonnicotine Pharmacotherapy on Smoking Behavior
Kotlyar, M., Golding, M., Hatsukami, D. K., & Jamerson, B. D. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.20.1530.34477 · Cited by 32
“Of five controlled studies published to date, two indicated that buspirone may promote smoking cessation, 37 two found no benefit, 40 and one reported buspirone to be helpful only in patients with a high level of baseline anxiety.(39) The two studies reporting benefit were relatively small, enrolling a total of 89 sub…”
Background
Metadata
- Authors
- Cinciripini, P. M., Lapitsky, L., Seay, S., Wallfisch, A., Meyer, W. J., & Van Vunakis, H.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1995-06
- Volume
- 15
- Issue
- 3
- Pages
- 182-191
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1982643847
- Cited by
- 73
- References
- 3
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo-Controlled Evaluation of the Effects of Buspirone on Smoking Cessation: Differences Between High- and Low-Anxiety Smokers. https://app.cochat.ai/papers/10.1097/00004714-199506000-00006
- The paper
- Cinciripini, P. M., Lapitsky, L., Seay, S., Wallfisch, A., Meyer, W. J., & Van Vunakis, H. (1995). A Placebo-Controlled Evaluation of the Effects of Buspirone on Smoking Cessation: Differences Between High- and Low-Anxiety Smokers. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199506000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.